Article

<i>TP53</i>mutation screening for patients at risk of myeloid malignancy

2024-02-08

Abstract excerpt

<h4>ABSTRACT</h4> There is increasing recognition of the risk of developing therapy-related myeloid malignancy, including after cellular therapy. While retrospective studies have implicated pre-existing TP53 mutated hematopoietic clones as a common causative mechanism, no prospective screening to identify those patients at greatest risk is currently possible. We demonstrate that ultradeep DNA-sequencing prior to t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 411dfb3c-19ec-5858-9434-3677ea09eca2
DOI: 10.1101/2024.02.06.24302401

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>TP53</i>mutation screening for patients at risk of myeloid malignancyDOI 10.1101/2024.02.06.24302401Read

TP53 mutation screening for patients at risk of myeloid malignancySemantic proximity Read

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AMLSemantic proximity Read

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.Semantic proximity Read

Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming projectSemantic proximity Read

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read

Comparison of<i>TP53</i>Mutations in Myelodysplasia and Acute Leukemia Suggests Divergent Roles in Initiation and ProgressionSemantic proximity Read

Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid NeoplasmsSemantic proximity Read

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.Semantic proximity Read

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.Semantic proximity Read